Original InvestigationPathogenesis and Treatment of Kidney Disease and HypertensionUse of Allopurinol in Slowing the Progression of Renal Disease Through Its Ability to Lower Serum Uric Acid Level
Section snippets
Methods
Eight hundred fifty-two patients were followed up in our renal clinic from April 2003 to April 2004 and screened for eligibility to participate in the study. Included subjects had to fulfill the following inclusion criteria: (1) presence of renal disease, defined as daily proteinuria greater than 0.5 g and/or an elevated serum creatinine (Cr) level greater than 1.35 mg/dL (>120 μmol/L) at baseline; and (2) in stable clinical condition in terms of general health and renal function (baseline
Results
Between April 2003 and April 2004, a total of 54 patients were enrolled in the study. Mean age of the allopurinol group was 47.7 ± 12.9 years, and of the control group, 48.8 ± 16.8 years. Male-female ratios were 9:4 and 13:15 for the treatment and control groups, respectively. Diabetes mellitus constituted 24% (treatment group) and 27% (control group) in our study population, and the majority of patients had preexisting hypertension (84%, treatment group; 73%, control group). Baseline
Discussion
Uric acid is a product of purine metabolism. After being filtered, uric acid is both reabsorbed and excreted in the proximal tubule through a voltage-sensitive urate channel and a urate-anion exchange mechanism. Hyperuricemia can be a result of either increased production or decreased excretion. In patients with renal disease, there is decreased uric acid urinary excretion, and whether this will give rise to hyperuricemia depends on the gastrointestinal excretory compensation.13 The prevalence
References (29)
- et al.
Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort
Am J Kidney Dis
(2004) - et al.
Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats
Kidney Int
(2005) - et al.
Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression
J Biol Chem
(1991) - et al.
Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice
Mol Cell
(1998) - et al.
Ineffectiveness of allopurinol in reduction of oxidative stress in diabetic patients; A randomized, double-blind placebo-controlled clinical trial
Biomed Pharmacother
(2004) - et al.
Precursors of essential hypertensionPulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries
Am J Epidemiol
(1990) - et al.
Serum uric acid and hypertensionThe Olivetti heart study
J Hum Hypertens
(1994) - et al.
Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey
JAMA
(2000) - et al.
Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy
Nephrol Dial Transplant
(2000) - et al.
Serum uric acid and renal prognosis in patients with IgA nephropathy
Nephron
(2001)
Hypouricemia and hyperuricemia in type 2 diabetesTwo different phenotypes
Eur J Clin Invest
Requiem for gouty nephropathy
Kidney Int
Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects
Hypertens Res
Hyperuricemia causes glomerular hypertrophy in the rat
Am J Nephrol
Cited by (0)
Support: None. Potential conflicts of interest: None.
Originally published online as doi:10.1053/j.ajkd.2005.10.006 on December 5, 2005.